Bio-Rad Remedi HS sales could double following FDA clearance, firm tells analysts.
This article was originally published in The Gray Sheet
BIO-RAD REMEDI HS DRUG PROFILING SYSTEM annual unit sales of 20-25 could double following FDA's recent clearance of a 510(k) for the product, James Bennett, Bio-Rad's chief operating officer, told analysts May 23 in New York City. The Remedi HS, which sells for about $100,000, was cleared by the agency in March. Since its introduction in 1990, Bio-Rad has placed about 150 of the systems with international customers and in U.S. hospitals that are using the system on an investigational basis.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.